Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Taxes (2023 - 2025)

Protalix BioTherapeutics has reported Current Taxes over the past 3 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Current Taxes at $2.9 million for Q4 2025, down 15.13% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 15.13% YoY), and the annual figure for FY2025 was $2.9 million, down 15.13%.
  • Current Taxes for Q4 2025 was $2.9 million at Protalix BioTherapeutics, up from $2.4 million in the prior quarter.
  • Over the last five years, Current Taxes for PLX hit a ceiling of $3.7 million in Q2 2025 and a floor of $2.4 million in Q3 2025.
  • Median Current Taxes over the past 3 years was $3.2 million (2024), compared with a mean of $3.2 million.
  • Biggest five-year swings in Current Taxes: increased 20.86% in 2024 and later dropped 15.13% in 2025.
  • Protalix BioTherapeutics' Current Taxes stood at $2.9 million in 2023, then increased by 20.86% to $3.5 million in 2024, then fell by 15.13% to $2.9 million in 2025.
  • The last three reported values for Current Taxes were $2.9 million (Q4 2025), $2.4 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.